Sivik Global Healthcare LLC grew its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 16.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,000 shares of the medical equipment provider's stock after purchasing an additional 20,000 shares during the quarter. Smith & Nephew SNATS comprises approximately 1.2% of Sivik Global Healthcare LLC's portfolio, making the stock its 26th biggest holding. Sivik Global Healthcare LLC's holdings in Smith & Nephew SNATS were worth $4,288,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Hexagon Capital Partners LLC boosted its holdings in Smith & Nephew SNATS by 63.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after buying an additional 406 shares during the period. Richards Merrill & Peterson Inc. boosted its holdings in shares of Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after acquiring an additional 1,000 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,701 shares during the period. Banque Transatlantique SA purchased a new position in shares of Smith & Nephew SNATS in the first quarter valued at $52,000. Finally, Opal Wealth Advisors LLC bought a new stake in shares of Smith & Nephew SNATS during the 1st quarter valued at $73,000. Hedge funds and other institutional investors own 25.64% of the company's stock.
Smith & Nephew SNATS Stock Performance
NYSE:SNN opened at $35.09 on Friday. The stock has a market cap of $14.97 billion, a P/E ratio of 16.24, a PEG ratio of 0.97 and a beta of 0.69. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The business's 50-day moving average price is $36.63 and its two-hundred day moving average price is $31.47. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $38.79.
Smith & Nephew SNATS Cuts Dividend
The business also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be given a dividend of $0.285 per share. The ex-dividend date is Friday, October 3rd. This represents a yield of 165.0%. Smith & Nephew SNATS's payout ratio is presently 26.39%.
Analyst Upgrades and Downgrades
Several brokerages have commented on SNN. Weiss Ratings restated a "hold (c+)" rating on shares of Smith & Nephew SNATS in a research note on Wednesday. Wall Street Zen lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Finally, Canaccord Genuity Group boosted their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research note on Monday, August 18th. Seven equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $36.00.
Read Our Latest Report on SNN
Smith & Nephew SNATS Profile
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
See Also
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
